undamentalytics Newsletter
Sign in

Stereotaxis, Inc. income statement

In fiscal 2025, Stereotaxis, Inc. reported revenue of $32.4m, up 20.3% on the year before, operating income of −$22.1m (a -68.3% margin) and net income of −$21.6m, or −$0.25 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue515442473835383231292927352827273230
Cost of revenue1716121511810811668121012121513
Gross profit343829322727272520242319231815151717
Research and development14121386565789810111010910
Selling and marketing293032211715161514131311121212121211
General and administrative15151713131211106566141414171818
Operating income−24−19−32−11−9−5−5−6−6−2−5−7−13−19−22−25−22−23
Interest expense53471333200————————
Net interest income—————————−000−001110
Net income−27−20−32−9−69−5−7−5−60−5−7−11−18−21−24−22−22
Diluted EPS−$0.63−$3.59−$5.84−$1.33−$5.95−$0.26−$0.35−$0.54−$0.32−$0.03−$0.10−$0.11−$0.16−$0.26−$0.27−$0.30−$0.25−$0.23
Diluted shares (average)—6m5m7m12m20m21m22m23m52m63m73m76m76m81m85m91m97m
EBITDA−22−17−30−9−8−5−5−6−5−2−5−7−13−18−21−24−21−22

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: POCI vs STXSOBIO vs STXSRVP vs STXSQTI vs STXS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Stereotaxis, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Stereotaxis, Inc.